Trial · NCT07028424
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
NCT07028424, Phase 2, Not yet recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment. Trials, record NCT07028424. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07028424
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
- NCT number
- NCT07028424
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 206 participants, estimated
- Lead sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Conditions
- PDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- Nal-IRI, Ciprofloxacin, Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, 5-Fluorouracil, Placebo
- First posted
- 2025-06-19
- Last updated
- 2025-07-01
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-month progression-free survival (PFS) rate post randomization Step 1 (R1) in Arm 1A | 6 months | To assess the efficacy of a 6-month PFS rate post R1 in patients with metastatic PDAC who received first-line (L1) NALIRIFOX with LV5FU2 (5-FU/leucovorin) maintenance strategy during Step 1 (Arm 1A). |
| Secondary | Progression-free survival first-line (PFS-L1) post randomization Step 1 (R1) in Arm 1A and in Arm 1B | up to 5 years | To assess PFS-L1 post R1 in Arm 1A and Arm 1B |
| Secondary | Progression-free survival (PFS) post NALIRIFOX reintroduction (PFS-reintro) in Arm 1A | up to 5 years | To assess PFS-reintro in Arm 1A |
| Secondary | Overall survival post randomization Step 1 (OS-R1) in Arm 1A and in Arm 1B | up to 5 years | To assess OS-R1 in Arm 1A and Arm 1B |
| Secondary | Overall response rate of first-line (ORR-L1) at 4 months in Arm 1A and in Arm 1B | 4 months | To assess ORR-L1 at 4 months in Arm 1A and Arm 1B, according to RECIST 1.1 |
| Secondary | Overall response rate post NALIRIFOX reintroduction (ORR-RI) in Arm 1A | up to 5 years | To assess ORR-RI in Arm 1A |
| Secondary | Best response rate of first-line (BRR-L1) in Arm 1A and in Arm 1B | up to 5 years | To assess BRR-L1 in Arm 1A and Arm 1B |
| Secondary | Best response rate of first-line after reintroduction of NALIRIFOX (BRR-L1R) in Arm 1A | up to 5 years | To assess BRR-L1R in Arm 1A |
| Secondary | Duration of disease control (DDC) in Arm 1A and in Arm 1B | up to 5 years | To assess DDC in Arm 1A and in Arm 1B |
| Secondary | Grade 3-4 adverse events (AEs)/serious AEs (SAEs) related to treatment | until 28 days after end of treatment visit | To assess safety (only grade 3-4 AEs/SAEs related to treatment in Arm 1A and Arm 1B, according to the NCI CTCAE v5.0 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07028424
GET https://conductscience.org/api/trials/v1/NCT07028424/registered